386 results on '"Howell, Sacha J"'
Search Results
2. CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisis
3. Incorporating progesterone receptor expression into the PREDICT breast prognostic model
4. Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
5. Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: Lower rates for 5 years post chemotherapy
6. Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420)
7. Population-based germline testing of BRCA1, BRCA2, and PALB2 in breast cancer patients in the United Kingdom: Evidence to support extended testing, and definition of groups who may not require testing
8. Metaplastic breast cancer and BRCA1: first strong evidence of a link
9. Breast cancer polygenic risk scores derived in White European populations are not calibrated for women of Ashkenazi Jewish descent
10. Deep learning models to predict mammographic density jointly on standard dose and low dose images
11. Pathogenic variant detection rate varies considerably in male breast cancer families and sporadic cases: minimal additional contribution beyondBRCA2, BRCA1andCHEK2
12. AI-based density prediction for breast cancer prevention: can we measure mammographic density in just one breast?
13. Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer
14. Extended gene panel testing in lobular breast cancer
15. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
16. Author Correction: Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock
17. Correction: Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women
18. Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women
19. Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock
20. Development of a breast cancer risk assessment and primary prevention pathway for women aged 30–39 years: Views of UK primary care providers on the role of primary care.
21. Correction To: Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420)
22. Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer
23. Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women
24. Tumor circadian clock strength influences metastatic potential and predicts patient prognosis in luminal A breast cancer
25. Capability and reliability of deep learning models to make density predictions on low dose mammograms
26. Feasibility and acceptability of offering breast cancer risk assessment to general population women aged 30–39 years: a mixed-methods study protocol
27. Germline testing of BRCA1, BRCA2, PALB2 and CHEK2 c.1100delC in 1514 triple negative familial and isolated breast cancers from a single centre, with extended testing of ATM, RAD51C and RAD51D in over 400.
28. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
29. Population based germline testing of BRCA1, BRCA2 and PALB2 in breast cancer patients in the UK: Evidence to support extended testing and definition of groups who may not require testing
30. Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
31. Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors
32. Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer
33. Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study
34. AI-based density prediction for breast cancer prevention: Can we measure mammographic density in just one breast?
35. Tumor circadian clock strength influences metastatic potential and predicts patient prognosis in luminal A breast cancer.
36. Breast density prediction from low and standard dose mammograms using deep learning: effect of image resolution and model training approach on prediction quality
37. 1688: Exposure of breast tissue in modern radiotherapy for lymphoma: a systematic review
38. Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?
39. Personalized prevention in high risk individuals: Managing hormones and beyond
40. Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants
41. Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
42. Subtype-specific circadian clock dysregulation modulates breast cancer biology, invasiveness, and prognosis.
43. Detection of pathogenic variants in breast cancer susceptibility genes in bilateral breast cancer
44. Correction: Evaluating the Acceptance and Usability of an App Promoting Weight Gain Prevention and Healthy Behaviors Among Young Women With a Family History of Breast Cancer: Protocol for an Observational Study
45. Germline testing of BRCA1, BRCA2, PALB2and CHEK2c.1100delC in 1514 triple negative familial and isolated breast cancers from a single centre, with extended testing of ATM, RAD51Cand RAD51Din over 400
46. Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling
47. The Role of Steroid Hormones in Breast and Effects on Cancer Stem Cells
48. Supplementary Figure 3 from Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms
49. Supplementary Methods from Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms
50. Supplementary Figure 2 from Targeting CXCR1/2 Significantly Reduces Breast Cancer Stem Cell Activity and Increases the Efficacy of Inhibiting HER2 via HER2-Dependent and -Independent Mechanisms
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.